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ABSTRACT
Aprataxin is the causative gene product for early-
onset ataxia with ocular motor apraxia and hypo-
albuminemia/ataxia with oculomotor apraxia type 1
(EAOH/AOA1), the clinical symptoms of which are
predominantly neurological. Although aprataxin has
been suggested to be related to DNA single-strand
break repair (SSBR), the physiological function of
aprataxin remains to be elucidated. DNA single-
strand breaks (SSBs) continually produced by
endogenous reactive oxygen species or exogenous
genotoxic agents, typically possess damaged
30-ends including 30-phosphate, 30-phosphoglycolate,
or 30-a, b-unsaturated aldehyde ends. These
damaged 30-ends should be restored to 30-hydroxyl
ends for subsequent repair processes. Here we
demonstrate by in vitro assay that recombinant
human aprataxin specifically removes 30-phospho-
glycolate and 30-phosphate ends at DNA 30-ends, but
not 30-a, b-unsaturated aldehyde ends, and can act
with DNA polymerase b and DNA ligase III to repair
SSBs with these damaged 30-ends. Furthermore,
disease-associated mutant forms of aprataxin lack
this removal activity. The findings indicate that
aprataxin has an important role in SSBR, that is, it
removes blocking molecules from 30-ends, and that
the accumulation of unrepaired SSBs with damaged
30-ends underlies the pathogenesis of EAOH/AOA1.
The findings will provide new insight into the
mechanism underlying degeneration and DNA
repair in neurons.
INTRODUCTION
Aprataxin is the causative gene product for early-onset
ataxia with ocular motor apraxia and hypoalbuminemia,
also called ataxia with oculomotor apraxia type 1 (EAOH/
AOA1) (1,2), which is characterized by early-onset
progressive ataxia, ocular motor apraxia, peripheral
neuropathy and hypoalbuminemia (3–6). Aprataxin inter-
acts with the X-ray repair cross-complementing group 1
protein (XRCC1) and poly(ADP-ribose) polymerase-1
(PARP-1), which are a scaﬀold protein and a molecular
nick sensor in DNA single-strand break repair (SSBR),
respectively (7–10), suggesting that aprataxin is asso-
ciated with SSBR. Consistent with these observations, the
lymphoblastoid cells from patients with EAOH/AOA1
show a high sensitivity to H2O2 and alkylating agents,
which cause DNA single-strand breaks (SSBs) (11). In
addition, aprataxin has the histidine triad (HIT) motif,
which functions as nucleotidyl hydrolases (12–15), and
the zinc ﬁnger motif, which is a DNA- or RNA-binding
motif. These ﬁndings led to the hypothesis that aprataxin
has catalytic activity in SSBR.
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bone of one strand of a DNA duplex. In neurons, DNA is
under continuous threat of damage byendogenous reactive
oxygen species (ROS) or exogenous environmental geno-
toxins, and more than tens of thousands of SSBs arise in
each cell per day (16). SSBs can arise directly from sugar
damage, or indirectly from base damage via the enzymatic
cleavage of the phosphodiester backbone as intermediate
products of SSBR (16). The formation of another type of
SSB is mediated by topoisomerase I (TOP1), which cleaves
one strand of a DNA duplex during transcription or DNA
replication (17,18). If SSBs are not repaired rapidly, they
can cause transcription blockage or they are converted to
lethal DNA double-strand breaks (DSBs), leading to cell
dysfunction and cell death (19).
Most SSBs are accompanied by the loss of a single
nucleotide; this loss must be ﬁlled by DNA polymerase
and subsequently sealed by DNA ligase. DNA polymerase
b (Pol b) and DNA ligase III (Lig3) are most commonly
employed for gap ﬁlling and ligation during SSBR (8).
SSBs arising directly from sugar damage or indirectly
from base damage typically possess damaged 30-ends:
30-phosphate, 30-phosphoglycolate (30-PG), or 30-a,
b-unsaturated aldehyde ends. Because these damaged
30-ends are not suitable for DNA polymerase or DNA
ligase, enzymatic processing is required in SSBR to restore
the damaged 30-ends to suitable 30-hydroxyl ends.
50-Polynucleotide kinase 30-phosphatase (PNKP) removes
damaged 30-phosphate ends, but not other damaged
30-ends. Apurinic/apyrimidinic endonuclease (APE1) can
remove 30-phosphate, 30-PG and 30-a, b-unsaturated
aldehyde ends (20). However, the 30-PG and 30-phosphate
removal activities of APE1 are  70-fold lower than the
AP endonuclease activity of APE1 (21–23). Therefore, it
is assumed that other enzymes can alternatively process
these damaged 30-ends.
In the present study, we hypothesized that aprataxin
removes damaged 30-ends and facilitates the repair of
SSBs. Here we show that aprataxin has a novel removal
activity with a unique substrate speciﬁcity toward
damaged 30-ends including 30-PG and 30-phosphate ends,
and that disease-associated mutant forms of aprataxin
lack this activity. The results indicate that aprataxin has
an important and direct role in SSBR, that is, it removes
blocking molecules from DNA 30-ends, and that neuro-
degeneration in EAOH/AOA1 may be caused by the
accumulation of unrepaired SSBs with damaged 30-ends.
MATERIALS AND METHODS
Expression and purification of recombinant aprataxin
The long-form human aprataxin cDNA (GenBank acces-
sion number NM_175073) was ampliﬁed by polymerase
chain reaction (PCR) using the primers 50-CCGGATC
CATGATGCGGGTGTGCTGGTTGG and 30-GGCTC
GAGTCACTGTGTCCAGTGCTTCCTG and the
cDNA library (Human Ovary Marathon-Ready cDNA:
Clonetech) as the template. The aprataxin cDNA frag-
ment was inserted into the BamHI/XhoI site of the
pFastBac
TM donor plasmid, and this plasmid was
transformed in DH10Bac
TM competent cells to transpose
into ‘Bacmids’ (Bac-to-Bac Baculovirus Expression
Systems, Invitrogen). Recombinant ‘Bacmids’ were puri-
ﬁed using the High Purity Plasmid Miniprep System
(Marligen), and infected to insect cells with the Cellfectin
reagent according to the manufacturer’s recommendation.
A high-titer viral stock was obtained, and Sf9 cells were
infected at a multiplicity of infection (MOI) of 10 for 72h.
Then, the cells were harvested and lysed in insect cell lysis
buﬀer (BD Pharmingen) with 1  Complete Mini (Roche
Diagnostic Corporation) for 30min at 48C. Recombinant
human aprataxin was ﬁrst puriﬁed by immobilized metal
aﬃnity chromatography (MagExtractor His-tag protein
puriﬁcation kit, TOYOBO). The extracts were fractio-
nated by gel ﬁltration column chromatography (AKTA
explorer 10S with HiLoad 16/60 Superdex 75pg column,
GE Healthcare) in 50mM Tris-HCl (pH 7.5) and 100mM
NaCl. These fractionated extracts were desalinized using
Slide-A-Lyzer dialysis cassettes (Pierce Biotechnology),
separated by denaturing sodium dodecyl sulfate-
polyacrylamide gel electrophoresis (SDS-PAGE), and
stained with Coomassie brilliant blue (CBB). Western
blotting was performed using an anti-Tetra-His antibody
(Quiagen) and an anti-aprataxin antibody (ab31841,
Abcom).
Recombinant human Pol b, PNKP and Lig3 were
expressed in silkworm Bombyx mori (Katakura). The
cDNA fragment of each protein was ampliﬁed by PCR
using the cDNA library (Human Ovary Marathon-Ready
cDNA: Clontech) as the template and then inserted into
pYNGHis (Katakura). The puriﬁed plasmid vector was
mixed with puriﬁed cysteine proteinase-deleted viral DNA
and then cotransfected in BmN cells of silkworm Bombyx
mori larvae. The obtained recombinant virus was used for
the infection of silkworm Bombyx mori pupae. Infected
pupae were incubated at 258C, and then frozen for 144h
postinoculation. Harvested pupae were lysed, and the His-
tagged protein was puriﬁed by immobilized metal aﬃnity
chromatography (MagExtractor His-tag protein puriﬁ-
cation kit, TOYOBO).
Mutant aprataxin cDNAs were produced using the
GeneTailer site-directed mutagenesis system (Invitrogen).
Wild-type long-form aprataxin (LA) cDNA, the forkhead-
associated (FHA) domain of aprataxin (1–114 amino
acids; FHA), the splicing variant of aprataxin (175–343
amino acids, GenBank accession number NP_7782411;
SA) and the mutant forms of aprataxin cDNA fragments
were inserted into the BamHI/XhoI site of pGEX-6P-3
(GE Healthcare Bio-Science Corp.). Glutathione S-
transferase (GST) fusion proteins were overexpressed in
Rosetta 2 (DE3) pLysS (Novagen) bacterial cells contain-
ing these plasmids. The bacterial cells were grown at 378C
until they reached an A600 of 1.0 and then induced with
1mM isopropyl-1-thio-D-galactopyranoside and grown
for another 3h before harvesting. Cell pellets were lysed
using BugBuster HT (Novagen) with EDTA-free complete
protease inhibitor cocktail (Sigma). The GST-tagged
proteins were puriﬁed using a GST fusion protein
puriﬁcation kit (Bulk GST Puriﬁcation Modules,
3798 Nucleic Acids Research, 2007, Vol. 35, No. 11GE Healthcare). Puriﬁed fractions were desalinized using
Slide-A-Lyzer dialysis cassettes (Pierce Biotechnology),
separated by denaturing SDS-PAGE, and stained with
CBB. Western blotting was performed using an anti-GST
antibody (GE Healthcare Bio-Science Corp.) and an anti-
aprataxin antibody (ab31841, Abcom).
Oligonucleotide substrates
The sequences of DNA substrates used were as follows:
FITC-21 (50-[FITC]CTACGTCAGATCTGCGGATGT-
30), 21-OH (50-CTACGTCAGATCTGCGGATGT[OH]-
30), 21-P (50-CTACGTCAGATCTGCGGATGT[P]-30),
24 (50-CTCTAGCACTTGAGGCTATCCATG-30), 23
(50-TCTAGCACTTGAGGCTATCCATG-30), 45 (50-
CATGGATAGCCTCAAGTGCTAGAGACATCCGC
AGATCTGACGTAG-30), FITC-21-PG (50-[FITC]CTA
CGTCAGATCTGCGGATGT-[PG]-30), FITC-21-Y (50-
[FITC]CTACGTCAGATCTGCGGATGT-[Y]-30), and
45/21(U) (50-[FITC]CTACGTCAGATCTGCGGATGU
CTCTAGCACTTGAGGCTATCCATG-30). 50-FITC-
labeled oligonucleotides were synthesized and puriﬁed by
high-performance liquid chromatography. A 50-FITC-
labeled 30-PG 21-mer oligonucleotide (FITC-21-PG) was
obtained from Thermo Electron Corporation. A 50-FITC-
labeled 30-phosphotyrosine 21-mer oligonucleotide (FITC-
21-Y) was purchased from Midland Certiﬁed Reagent
Company. A 50-FITC-labeled 21-mer oligonucleotide with
30-phospho-a, b-unsaturated aldehyde was prepared using
uracil DNA glycosylase (Invitrogen) and endonuclease III
(BioLabs). To generate an apurinic/apyrimidinic (AP) site
at the 21st uracil from 50,1 0mM oligonucleotide FITC-45/
21(U) was incubated with uracil DNA glycosylase (2 unit)
for 1h at 378C in a mixture containing 20mM Tris-HCl
(pH 8.4), 10mM MgCl2 and 50mM KCl. The reaction
product was annealed with 10mM oligonucleotide 45.
Annealed oligonucleotides (2mM) were treated with endo-
nuclease III according to the manufacturer’s instructions
to generate the 50-FITC-labeled 21-mer oligonucleotide
with 30-phospho-a, b-unsaturated aldehyde.
30-Endprocessing assay
To analyze the activity of aprataxin to remove
30-phosphate, 1pmol of oligonucleotides phosphorylated
at the 30-end was incubated in a mixture containing
100mM Tris-HCl (pH 6.0), 10mM MgCl2,1 0m Mb-ME
and 0.1mg/ml BSA with the indicated protein (25, 50 and
100nM aprataxin, and 50nM PNKP) for 1h at 378C. To
analyze the activity of aprataxin to remove 30-PG, 30-
phospho-a, b-unsaturated aldehyde or 30-phosphotyrosine
ends, 50-FITC-labeled 21-mer oligonucleotides with 30-PG,
30-phospho-a, b-unsaturated aldehyde or 30-phosphotyro-
sine ends were incubated with aprataxin (25, 50 and
100nM), APE1 and TDP1 in a mixture containing 25mM
Tris-HCl (pH 7.5), 10mM MgCl2, 0.5mM ATP, 0.1mg/
ml BSA and 1mM DTT for 1h at 378C. Reactions were
stopped by adding an equal volume of gel-loading buﬀer
(80% formamide, 10mM EDTA and 0.1% bromophenol
blue). The products were separated by electrophoresis in a
denaturing 20% polyacrylamide-8M urea gel and
visualized using a Typhoon 9400 scanner (GE
Healthcare). We used APE1 (TREVIGEN) and TDP1
(Abnova Corporation) as the positive controls.
GMP- and AMP-lysine hydrolase assay
GMP- and AMP-lysine hydrolysis assay was performed
using a method originally developed for FHIT with a
ﬂuorogenic substrate, GpppBODYPY (Molecular Probes)
(15). We followed the protocol of this method previously
described with a slight modiﬁcation. Brieﬂy, 100mM
GpppBODYPY or ApppBODYPY was incubated with
the indicated amounts of recombinant proteins (His-LA,
LA, SA and FHA) for 1h at 378Ci n2 0mlo f2 0m MN a
HEPES (pH 7.0), 0.5mM MnCl2 and 0.2mg/ml BSA.
Reactions were stopped by adding an equal volume of gel-
loading buﬀer (80% formamide, 10mM EDTA and 0.1%
bromophenol blue). The products were separated by
electrophoresis in a denaturing 20% polyacrylamide–8M
urea gel and visualized using a Typhoon 9400 scanner (GE
Healthcare). We used Fhit (Upstate) as the positive
control.
Preparation ofDNA 50-adenylates
DNA 50-adenylate was essentially prepared as previously
described (24). Brieﬂy, a 12.5mM5 0-phosphate 30-FITC-
labeled 24-mer oligonucleotide (P-24-FITC: 50-
[P]CTCTAGCACTTGAGGCTATCCATG[FITC]-30)
was annealed with a 25mM3 0-phosphate 21-mer oligonu-
cleotide (21-P: 50-CTACGTCAGATCTGCGGATGT[P]-
30) and 25mM complementary oligonucleotide 45. The
annealed oligonucleotides were treated with 100nM T4
DNA ligase in ligation buﬀer (50mM Tris-HCl (pH7.5),
10mM MgCl2, 5mM DTT, 25mg/ml BSA and 1mM
ATP) overnight at 378C. Because the nick cannot be
ligated owing to 30-end blocking with phosphate, the
adenylation of the 50-end occurs as an abortive ligation
intermediate. The reaction product, 50-AMP 30-FITC-
labeled 24-mer oligonucleotide (AMP-24-FITC), was then
denatured and puriﬁed by separation on a denaturing
20% polyacrylamide–8M urea gel. Following gel extrac-
tion, AMP-24-FITC was annealed with a 30-hydroxyl
21-mer oligonucleotide (21-OH) and oligonucleotide 45.
DNA 50-adenylate hydrolysis assay
DNA 50-adenylate hydrolysis assay was performed as
described previously with a slight modiﬁcation (25). In
brief, the 45-mer duplex DNA harboring a nick with
50-adenylate ends was incubated with aprataxin or PNKP
in a mixture containing 50mM Tris-HCl (pH 7.5), 1mM
EDTA, 5mM DTT for the indicated times at 378C.
Reactions were stopped by adding an equal volume of gel-
loading buﬀer (80% formamide, 10mM EDTA and 0.1%
bromophenol blue). The products were separated and
visualized as described above.
Reconstitution ofSSBR
For the reconstitution of DNA repair, 50-FITC-labeled
30-phosphate 21-mer oligonucleotides ðFITC-21-PO
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were annealed with 45- and 23-mer oligonucleotides in
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8.0) and 1mM NaCl to form SSBs with 30-end blocking
with phosphate. The 50-FITC-labeled 30-hydroxyl oligo-
nucleotide (FITC-21-OH) was used as the control of SSBs.
For another DNA repair assay, FITC-21-PG oligonucleo-
tides were annealed with 45- and 23-mer oligonucleotides
to form SSBs with 30-end blocking with PG. These
substrates were incubated with Pol b, Lig3 and aprataxin
for 90min at 378C. Reaction was stopped by adding an
equal volume of gel-loading buﬀer. The products were
separated by electrophoresis in a denaturing 20%
polyacrylamide–8M urea gel and visualized using a
Typhoon 9400 scanner (GE Healthcare).
RESULTS
Aprataxinremoves 30-phosphate and
30-phosphoglycolate ends
We constructed a histidine-tagged long-form human
aprataxin (His-LA) using the baculovirus-protein-
expression system (Figure 1A). His-LA was puriﬁed by
a standard technique, followed by further puriﬁcation by
immobilized metal aﬃnity and gel ﬁltration column
chromatography to remove any contamination by other
proteins. A single band, which was reactive to the anti-
aprataxin antibody, was observed by CBB staining for
fractions from 14 to 19 (Figure 1C and E). The aprataxin-
rich fraction (No. 15, Figure 1B–E) was used in the
following studies.
To investigate the enzymatic activity of aprataxin
against damaged 30-ends, we examined the 30-end proces-
sing activities of the recombinant aprataxin employing
various 30-end-modiﬁed oligonucleotides as substrates.
When 30-phosphate oligonucleotides were used as sub-
strates, the 30-phosphatase activity of aprataxin was clearly
demonstrated by the mobility shift on a denaturing 20%
polyacrylamide–8M urea gel, in which 30-phosphate oligo-
nucleotides were electrophoresed faster than 30-hydroxyl
oligonucleotides (Figure 2A). By treating 30-phosphate
oligonucleotides with aprataxin, the bands corresponding
to 30-hydroxyl oligonucleotides appeared in a concentra-
tion-dependent manner (Figure 2A, lanes 3–5). Next, we
determined whether aprataxin removes 30-PG ends.
Notably, as shown in Figure 2B, aprataxin removed
30-PG ends and generated 30-hydroxyl ends (Figure 2B).
In contrast, aprataxin failed to remove 30-a, b-unsaturated
aldehyde or 30-phosphotyrosine ends under the same
conditions as those in which aprataxin removed 30-
phosphate or 30-PG ends (Figure 2C and D). These results
indicate that aprataxin has 30-end processing activities
toward 30-phosphate and 30-PG ends, but not toward 30-a,
b-unsaturated aldehyde or 30-phosphotyrosine ends.
FHA domain of aprataxinand disease-associated
mutant formsof aprataxinlack 30-phosphatase and
30-phosphoglycolate hydrolase activities
To conﬁrm the 30-phosphatase and 30-PG hydrolase activi-
ties and determine the catalytic domain of aprataxin, we
constructed ﬁve types of the aprataxin fusion protein
including wild-type full-length aprataxin (long-form apra-
taxin, LA), two types of full-length mutant form of apra-
taxin(P206LandV263G),whicharemostfrequentlyfound
in Japanese patients, the N-terminal FHA domain (FHA)
of aprataxin, and aprataxin without the FHA domain
(short-form aprataxin, SA) in the bacterial expression
system (Figure 3A and B) (1). The GST-tagged long-form
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Figure 1. Expression and puriﬁcation of recombinant aprataxin in baculovirus expression system. (A) Construct of His-tagged long-form aprataxin
(His-LA) expressed using Bac-to-Bac Baculovirus Expression System. (B) Chromatogram of gel-ﬁltered aprataxin. Following immobilized metal
aﬃnity chromatography, the aprataxin-rich fraction was puriﬁed by gel ﬁltration column chromatography. A major peak was observed for each of
the fractions from 13 to 20 in the chromatogram. (C) The fractionated extracts were separated by SDS-PAGE and stained with Coomassie brilliant
blue (CBB). A 39-kDa single band is detected for each of the fractions from 14 to 19. Western blot analysis using the anti-His antibody (D) and anti-
aprataxin antibody (E) shows a 39-kDa immunoreactive product in each of the fractions from 13 to 21.
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lase activities comparable to those of His-LA obtained
from the baculovirus expression system (Figure 4A and B).
Although SA removed 30-phosphate and 30-PG (Figure 4A
and B), its removal activity was lower than that of LA.
FHA did not show removal activity (Figure 4A and B).
Next, we examined whether mutant forms of aprataxin
remove30-phosphate and30-PGends.Although themutant
aprataxin proteins were unstable, we were able to produce
full-length mutant forms of aprataxin (Figure 3B). These
puriﬁed mutant proteins contained a  63kDa form, that
is, full-length aprataxin and a  46kDa form that retained
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Figure 2. 30-End processing by aprataxin. (A) Aprataxin removes 30-phosphate. The 50-FITC-labeled 30-phosphate ð30-PO
 
3 Þ oligonucleotide was
incubated in the absence (lane 2) or presence of aprataxin at diﬀerent concentrations (25, 50 and 100nM, lanes 3–5). A band with the same size as
that of the 30-hydroxyl (30-OH) oligonucleotide (lane 1) appears in lanes with aprataxin (lanes 3–5). 50-Polynucleotide kinase 30-phosphatase (PNKP)
was used as the positive control (lane 6). Reaction products were separated by 20% PAGE and visualized using a ﬂuorescence gel scanner.
(B) Aprataxin removes DNA 30-phosphoglycolate. The 50-FITC–labeled 30-phosphoglycolate (30-PG) oligonucleotide was incubated in the absence
(lane 1) or presence of aprataxin at diﬀerent concentrations (25, 50 and 100nM, lanes 2–4). The amount of the 30-OH oligonucleotide increases with
aprataxin concentration (lanes 2–4). Apurinic/apyrimidinic endonuclease (APE1) was used as the positive control (lane 5). (C) Aprataxin fails to
remove 30-a, b-unsaturated aldehyde. The 50-FITC-labeled 30-a, b-unsaturated aldehyde (30-UA) oligonucleotide was incubated in the absence (lane 1)
or presence of aprataxin at diﬀerent concentrations (25, 50 and 100nM, lanes 2–4). The amount of the 30-UA oligonucleotide does not decrease
with increasing aprataxin concentration (lanes 2–4). The 30-OH oligonucleotides were generated in the presence of APE1 (lane 5). The faint
smear corresponding to the 30-UA oligonucleotide in lanes 1–5 is an artifact generated under the electrophoresis conditions employed. (D) Aprataxin
fails to remove 30-phosphotyrosine end. The 50-FITC-labeled 30-phosphotyrosine (30-Y) oligonucleotide was incubated in the absence (lane 1) or
presence of aprataxin at diﬀerent concentrations (25, 50 and 100nM, lanes 2–4). The amount of the 30-Y oligonucleotide do not decrease
with increasing aprataxin concentration (lanes 2–4). 30-PO3 oligonucleotides were generated in the presence of tyrosyl-DNA phosphodiesterase 1
(TDP1) (lane 5).
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phosphate or 30-PG ends (Figure 4A and B).
The aﬃnity and catalytic activity of these aprataxin
proteins for these two substrates are shown in Table 1. LA
showed the highest 30-phosphatase and 30-PG hydrolase
activities, whereas SA showed the activities less than one-
half of those of LA. FHA, P206L and V263G lacked the
activities. These results indicate that the C-terminal region
of aprataxin, which includes the HIT motif, is indis-
pensable for these activities and the N-terminal region of
1–174 amino acids might enhance these activities.
We compared these activities of LA with those of
PNKP or APE1 in parallel experiments. The turnover
number (Kcat) of the 30-phosphatase activity of LA was
10-fold lower than that of PNKP, whereas the Kcat of the
30-phosphatase activity of PNKP under our conditions
was lower than that previously reported (23) (Table 1).
On the other hand, the Kcat of the 30-PG hydrolase activity
of LA was  20-fold higher than that of APE1.
Substratespecificity of aprataxin
To investigate the substrate speciﬁcity of aprataxin, we
compared the DNA 30-phosphatase and 30-PG hydrolase
activities of aprataxin on single-stranded (ss) and double-
stranded (ds) DNAs (Figure 5). The 30-phosphatase
activity of LA on recessed, gapped or nicked ds DNA is
approximately one-half of that on ss DNA (Figure 5A–C).
In contrast, the 30-PG hydrolase activity of LA on both ss
and gapped ds DNA with 30-PG ends is 1.5-fold higher
than that on recessed or nicked ds DNA (Figure 5D–F).
Aprataxin removes adenylateresidues covalently linked to
50-phosphate ends, and disease-associated mutantforms of
aprataxin lackthe activity
As aprataxin has been reported to have GMP- and AMP-
lysine hydrolase activities, which are present in most
proteins of the HIT superfamily (12–15), we investigated
the GMP- and AMP-lysine hydrolase activities of apra-
taxin employing GpppBODIPY and ApppBODIPY as
substrates. The full-length aprataxin fusion proteins His-
LA and LA showed very low or no GMP- or AMP-lysine
hydrolase activity at the same or a higher concentration
used for the 30-end processing assay (Figure 6A and B).
Recently, Ahel et al. have shown that aprataxin
removes the adenylate residues on 50-ends of SSBs via its
hydrolase activity, thus resolving the abortive DNA liga-
tion intermediates (25). Therefore, we investigated the
50-adenylate monophosphate (AMP) removal activity of
our GST-aprataxin fusion proteins. As similarly observed
in their previous study (25), LA removed an adenylate
residue from a 50-end of nicked ds DNA (Figure 7A).
In addition, SA showed a much lower 50-AMP removal
activity than LA, and FHA and disease-associated mutant
forms (P206L and V263G) of aprataxin lacked the activity
(Figure 7B and C).
Reconstitution of SSBR by recombinant human aprataxin,
Pol band Lig3
To conﬁrm that the 30-end processing activity of aprataxin
is suﬃcient for SSBR by following the reactions carried
out by Pol b and Lig3, we then reconstituted SSBR using
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Figure 3. Expression of recombinant GST-aprataxin fusion protein. (A) Constructs of GST-aprataxin fusion proteins. Constructs of GST fusion
protein containing full-length aprataxin (long-form aprataxin, LA), the C-terminal region of aprataxin (short-form aprataxin, SA), the N-terminal
FHA domain of aprataxin (FHA) and full-length aprataxin with P206L or V263G (P206L, V263G). (B) Expression and puriﬁcation of GST-
aprataxin fusion proteins. Recombinant GST fusion proteins containing LA (lanes 1, 6 and 11), SA (lanes 2, 7 and 12), FHA (lanes 3, 8 and 13),
P206L (lanes 4, 9 and 14) and V263G (lanes 5, 10 and 15) were expressed in the bacterial expression system. Puriﬁed products were analyzed by CBB
staining (left panel), and western blotting using the anti-GST antibody (middle panel) or anti-aprataxin antibody (right panel).
3802 Nucleic Acids Research, 2007, Vol. 35, No. 11gapped ds DNA with damaged 30-ends as substrates.
In this assay, aprataxin was assumed to restore damaged
30-ends including 30-phosphate and 30-PG ends to
30-hydroxyl ends that are suitable for Pol b and Lig3
(Figure 8A and B, right panel). First, we incubated the
gapped ds DNA consisting of 30-phosphate 21-mer
oligonucleotides and 50-phosphate 23-mer oligonucleo-
tides annealed to complementary 45-mer oligonucleotides
with Pol b and Lig3 in the presence or absence of His-LA.
Here, 45-mer products were generated only in the presence
of His-LA (Figure 8A, left panel). Next, we incubated
gapped ds DNA consisting of 30-PG 21-mer oligonucleo-
tides and 50-phosphate 23-mer oligonucleotides annealed
to complementary 45-mer oligonucleotides with Pol b and
Lig3 in the presence or absence of His-LA. As expected,
45-mer products were generated only in the presence of
aprataxin (Figure 8B, left panel). These results clearly
indicate that the 30-phosphate and 30-PG removal activ-
ities of aprataxin are suﬃcient for the 30-end processing in
reconstituted SSBR with Pol b and Lig3.
DISCUSSION
Here, we show that aprataxin speciﬁcally removes
damaged 30-ends including 30-PG and 30-phosphate ends.
Through this action, aprataxin might act with DNA
polymerase and ligase to repair SSBs with these damaged
30-ends. In addition, the C-terminal region of aprataxin
is responsible for the removal activity and the region of
1–174 amino acids of aprataxin might enhance the
A
B
3′-OH 3′-PO3
−
LA     SA    FHA    P206L        V263G
3′-PO3
−
3′-OH
Protein
0    30   60    0   30   60   0   30   60    0   30   60  0   30   60  (min) Time
1    2    3     4    5   6   7    8    9   10   11   12   13  14   15   16 Lane
3′-PO3
−/OH   3′-PG
LA        SA FHA     P206L        V263G
3′-PO3
−
3′-OH
Protein  
1    2    3     4    5   6   7    8    9    10  11   12   13    14  15   16  17 Lane
0   30   60    0   30   60   0   30   60    0   30   60    0   30   60  (min) 
3′-PG
Time
Figure 4. Disease-associated mutant forms of aprataxin lack their 30-end processing activity. (A) Mutant forms of aprataxin fail to remove 30-
phosphate. The 50-FITC-labeled 30-phosphate ð30 -P O
 
3 Þ oligonucleotide was incubated in the presence of 50nM recombinant GST fusion proteins
containing LA (lanes 2–4), SA (lanes 5–7), FHA (lanes 8–10), P206L (lanes 11–13), and V263G (lanes 14–16) at diﬀerent incubation times (0, 30 and
60min). A band of the same size as that corresponding to the 30-hydroxyl (30-OH) oligonucleotide (lane 1) appears in lanes with LA (lanes 3 and 4).
SA showed a weak phosphatase activity (lanes 5–7). Neither FHA, P206L nor V263G showed phosphatase activity (lanes 8–16). (B) Mutant forms of
aprataxin fail to remove 30-phosphoglycolate. The 50-FITC-labeled 30-PG oligonucleotide was incubated in the presence of 50nM recombinant GST
fusion proteins containing LA (lanes 3–5), SA (lanes 6–8), FHA (lanes 9–11), P206L (lanes 12–14) and V263G (lanes 15–17) at diﬀerent incubation
times (0, 30 and 60min). A band of the same size as that corresponding to the 30-OH oligonucleotide (lane 2) appears in lanes with LA (lanes 3 and
4). SA showed a weak 30-PG hydrolase activity (lanes 6–8). Neither FHA, P206L nor V263G removed 30-PG (lanes 9–17).
Table 1. Enzymatic activity of recombinant forms of aprataxin determined using 30-phosphate and 30-phosphoglycolate oligonucleotides as substrates
LA SA FHA P206L V263G PNKP APE1
30-Phosphate
Kcat (s
 1) 0.00027 0.00007 0.00015 0.00001 50.00002 50.00002 50.00002 0.00262 0.00022
Km (nM) 129 76 251 58 228 124
30-Phosphoglycolate
Kcat (s
 1) 0.00287 0.00039 0.00160 0.00009 50.00002 50.00002 50.00002 0.00014 0.00001
Km (nM) 231 37 292 31 61 28
GST fusion proteins containing full-length aprataxin (long-form aprataxin, LA), the C-terminal region of aprataxin (short-form aprataxin, SA), the
N-terminal FHA domain of aprataxin (FHA), full-length aprataxin with P206L (P206L) and full-length aprataxin with V263G (V263G) were used.
Nucleic Acids Research, 2007, Vol. 35, No. 11 3803removal activity. Furthermore, the disease-associated
mutant forms of aprataxin P206L and V263G lack the
removal activity, strongly suggesting that the loss of
the removal activity of aprataxin is closely linked to the
pathogenesis of EAOH/AOA1.
The removal of damaged 30-ends is important for repair-
ing SSBs. SSBs arising directly from sugar damage usually
possess 30-phosphate or 30-PG ends, whereas SSBs arising
indirectly from base damage, via the enzymatic cleavage of
the DNA backbone, possess 30-a, b-unsaturated aldehyde,
or 30-phosphate ends (16,26). The formation of another
type of SSB is mediated by TOP1, which cleaves one strand
of a ds DNA during transcription or DNA replication
and covalently binds at the 30-ends with the tyrosyl-DNA
phosphodiester linkage (17) (Figure 9). Several enzymes
including a multiprotein complex with XRCC1 have
been proposed as candidates for removing these damaged
30-ends. PNKP might restore damaged 30-phosphate
ends, but not other damaged 30-ends (23,27). APE1 is
assumed to remove damaged 30-phosphate, 30-PG or 30-a,
b-unsaturated aldehyde ends; however, its enzymatic
activity for removing 30-phosphate or 30-PG is extremely
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Figure 5. Aprataxin 30-end processing activities on ss and ds DNA substrates. (A–C)3 0-Phosphatase activity of aprataxin on ss and ds DNA
substrates. (A) The ss, recessed, one-nucleotide gapped and nicked DNA substrates with 30-phosphate ends used are shown schematically. (B)
Aprataxin preferentially acts on ss DNA. The substrates were incubated with 20nM LA for the indicated times (0, 30, 60 and 90min) at 378C.
Products were separated by denaturing PAGE and visualized using a Typhoon 9400 scanner (GE Healthcare). (C) Production rates in each reaction
were quantiﬁed by ImageQuant TL (GE Healthcare). Error bars indicate standard errors for more than three independent experiments. (D–F)3 0-PG
hydrolase activity of aprataxin on ss and ds DNA substrates. (D) The ss, recessed, one-nucleotide gapped and nicked DNA substrates with 30-PG
ends used are shown schematically. (E) Aprataxin preferentially acts on ss and gapped DNA. The substrates were incubated with 20nM LA for the
indicated times (0, 30, 60 and 90min) at 378C. (F) Production rates in each reaction were quantiﬁed as described above.
3804 Nucleic Acids Research, 2007, Vol. 35, No. 11lower than its AP endonuclease activity (21–23). The
results using fusion proteins expressed in baculovirus and
bacterial expression systems clearly showed that aprataxin
restores the damaged 30-PG and 30-phosphate ends to
30-hydroxylends,butnot30-a,b-unsaturatedaldehydeends
nor phosphotyrosine ends. Moreover, the 30-PG removal
activity of aprataxin is higher than that of APE1 and
prefersthegappeddsDNAaswellasssDNA,althoughthe
30-phosphate removal activity of aprataxin is lower than
that of PNKP and prefers the ss DNA, not ds DNA. The
results suggest that aprataxin is associated with the
removal of damaged 30-ends, particularly 30-PG ends,
directly induced by sugar damage, whereas APE1 is asso-
ciated with the removal of damaged 30-a, b-unsaturated
aldehyde ends induced by base damage as well as the
endonucleolytic cleavage of an AP site (Figure 9A and B).
By contrast, although both PNKP and aprataxin might
restore damaged 30-phospohate ends, (Figure 9B and C),
these proteins are found in mutually exclusive complexes
with XRCC1 (28); therefore, they might function indepen-
dently of each other in the repair of SSBs induced by sugar
damage (Figure 9B and C). The precise physiological roles
of PNKP and aprataxin in SSBR, however, await further
investigations.
In DNA ligation, DNA ligase transfers AMP residues
to 50-ends of the DNA breaks and catalyzes the displace-
ment of the adenylate residues on 50-ends by attacking the
adjacent 30-hydroxyl group. When 30-ends are damaged
and non-ligated, the adenylate residues remain on 50-ends
of SSBs as abortive DNA-ligation intermediates.
Recently, Ahel et al. have shown that aprataxin removes
the adenylate residues on 50-ends of SSBs (25). As reported
in their article (25), aprataxin used in the present study
also removed an adenylate residue from a 50-end of nicked
ds DNA. These results indicate that aprataxin contributes
to processing the ‘dirty ends’, both 30- and 50-ends, of the
DNA breaks. Furthermore, the disease-associated mutant
forms of aprataxin lost their 30- and 50-end processing
activities, suggesting the importance of the activities for
EAOH/AOA1pathogenesis.Todeterminethemainphysio-
logical role of aprataxin in SSBR, we have to show the
accumulation of SSBs with these dirty ends in tissues from
patients with EAOH/AOA1 in future studies.
The clinical phenotype of EAOH/AOA1 is speciﬁcally
restricted to the nervous system, raising the possibility that
the activity of aprataxin to remove 30-phosphate or 30-PG
ends plays an important role in neurons. Tyrosyl-DNA
phosphodiesterase 1 (TDP1), the causative gene product
for spinocerebellar ataxia with axonal neuropathy type 1
(SCAN1), removes the TOP1 peptide from 30-ends in
SSBs induced by TOP1. In addition to its tyrosyl-DNA
phosphodiesterase activity, TDP1 has been also proposed
to remove 30-PG ends and function in the repair of SSBs
induced by oxidative stress (17,29). The clinical phenotype
of SCAN1 is similar to that of EAOH/AOA1, because
they include cerebellar degeneration, posterior column
involvement and peripheral axonal neuropathy without
predisposition to malignancy (30). These similarities
between EAOH/AOA1 and SCAN1 suggest that the
removal of damaged 30-ends, particularly those induced
by oxidative stress, is crucial for the viability and function
of neurons, in particular Purkinje cells and dorsal root
ganglion cells.
The unique properties of neurons including a high rate
of ROS production and a high transcriptional activity
may lead to the generation of more SSBs compared with
non-neuronal cells. Furthermore, although mitotic cells
can utilize a homologous recombination machinery to
compensate for a defect in SSBR, postmitotic neurons
are unable to repair damaged DNA molecules in a DNA-
replication-dependent manner and they are highly depen-
dent on SSBR for DNA integrity. Therefore, neurons
might be vulnerable to a defect in SSBR. The reason why
a speciﬁc neuronal subtype is vulnerable to impairment
of the aprataxin-dependent or TDP1-dependent SSBR
system remains to be elucidated. Further studies on the
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ApppBODIPY (B) was incubated with recombinant His-tagged long-
form aprataxin obtained from the baculovirus expression system
(His-LA, lanes 4–6), recombinant GST fusion proteins containing LA
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Nucleic Acids Research, 2007, Vol. 35, No. 11 3805mechanism underlying neuronal death and dysfunc-
tion caused by a defect in SSBR should provide new
insights into therapeutic approaches for neurodegenera-
tive disorders.
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Figure 7. Removal of adenylate residues from 50-ends by aprataxin. (A) Aprataxin removes AMP from 50-ends of nicked ds DNA. The 45-mer ds
DNA harboring a nick with 50-AMP ends was incubated with the indicated amounts of aprataxin for 1h. A band of the same size as that
corresponding to the 50-phosphate ð50 -P O
 
3 Þ oligonucleotide appears in lanes with aprataxin. PNKP was used as the negative control. (B) Mutant
forms of aprataxin fail to remove 50-AMP. The 45-mer ds DNA harboring a nick with 50-AMP ends was incubated in the presence of 50nM
recombinant GST fusion proteins containing LA (lanes 2–4), SA (lanes 5–7), FHA (lanes 8–10), P206L (lanes 11–13) and V263G (lanes 14–16) at
diﬀerent incubation times (0, 30 and 60min). SA showed a lower 50-AMP hydrolysis activity (lanes 5–7) than LA. Neither FHA, P206L nor V263G
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